A theme under which 6254 advances region-specific sales initiatives in Japan, South Korea, Greater China and Taiwan, the United States, Singapore and India, along with product-specific measures including those for the pharmaceutical industry, based on the medium-term management plan “HiPES-2023 (Revised).” The aim is to improve business profitability through expanded sales of UF membrane systems, a focus on profitability and cost reductions.